Navigation Links
United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
Date:2/15/2011

tion, future events or any other reason.

Remodulin and Tyvaso are registered trademarks of United Therapeutics Corporation.

Adcirca is a registered trademark of Eli Lilly and Company.

UNITED THERAPEUTICS CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share data)Three Months Ended December 31,Year Ended December 31,2010200920102009Revenues:Net product sales

$

163,445$

105,945$

591,881$

357,870Service sales

2,7382,69710,75310,751License fees

2942811,1971,227Total revenues

166,477108,923603,831369,848Operating expenses:Research and development

62,25541,032166,761122,188Selling, general and administrative

74,99856,577199,600176,338Cost of product sales

18,53612,23367,71640,890Cost of service sales

1,6371,2635,7494,431Total operating expenses

157,426111,105439,826343,847(Loss) income from operations

9,051(2,182)164,00526,001Other income (expense):Interest income

6291,0052,9395,146Interest expense

(5,459)(3,659)(19,714)(12,875)Equity loss in affiliate

(30)(42)(160)(141)Other, net

314145769636Total other (expense) income, net

(4,546)(2,551)(16,166)(7,234) Income (loss) before income tax

4,505(4,733)147,83918,767Income tax benefit (expense)

5,0391,403(41,923)695Net income (loss)

$

9,544$

(3,330)$

105,916$

19,462Net income (loss) per common share:Basic

$

0.17$

(0.06)$

1.89$

0.37Diluted

$

0.15$

(0.06)$

1.78$

0.35Weighted average number of common shares outstanding:Basic

57,18753,92656,14253,314Diluted

61,71553,92659,51656,133SELECTED CONSOLIDATED BALANCE SHEET DATA(In thousands)December 31,20102009Cash, cash equivalents and marketable securities (excluding restricted amounts of $5,122 and $39,976, respectively)

$

759,932$

378,120Tota
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
2. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
3. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
4. United Therapeutics to Announce Third Quarter 2008 Financial Results Before Market Open on Thursday, October 30, 2008
5. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
6. Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States
7. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
8. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
9. United Therapeutics Reports Third Quarter 2008 Financial Results
10. Lilly Contributes $11.1 Million to United Way Annual Campaign
11. First United Kingdom Patients Treated With Percutaneous MitraClip(R) System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014   Sigma-Aldrich Corporation ... has entered into a new gene editing partnership ... Vector Core. Under the partnership, Sigma-Aldrich will provide ... design consultation, and dedicated gene editing bioinformaticians. ... editing-based research at the U-M Medical School. One ...
(Date:9/18/2014)... 2014 SeqLL Inc., the owner ... announced today the closing of a $1M Series-A ... Genomic Diagnostic Technologies, will increase the power of ... Founded in March 2013 by Daniel Jones, a ... Helicos BioSciences, SeqLL has continued to offer Helicos’ ...
(Date:9/18/2014)... lab can be pretty expensive. Now a team led ... an open-source library of designs that will let scientists ... equipment: the syringe pump. , Syringe pumps are used ... delivery or mixing chemicals in a reaction. They can ... Joshua Pearce and his team of Michigan Tech students ...
(Date:9/18/2014)... a new microscopy technology that allows them to ... resolution. , Dubbed "Complementation Activated Light Microscopy" (CALM), ... an order of magnitude finer than conventional optical ... biomolecules at the nanometer scale. , In a ... Communications , the researchers behind CALM used it ...
Breaking Biology Technology:Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2Doing science just got cheaper -- and faster 2Scientists pioneer microscopy technique that yields fresh data on muscular dystrophy 2
... to Screen Donated Blood for Hepatitis B, as well ... and Semi-Automated Instrument Systems -, SAN DIEGO, Aug. ... that the US Food and Drug Administration,(FDA) has approved ... to screen donated blood for the hepatitis B,virus (HBV). ...
... Stock Exchange Symbol: MS, - Milestone triggers ... - EDMONTON, Aug. 13 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), today,announced that the ... trial has conducted the scheduled interim analysis of ...
... Mentice, Inc. and MATC have,forged a relationship that ... multiple,and mutually beneficial projects to further advance the ... throughout North America., Mentice,s Procedicus VIST Simulator ... physician to gain exposure to routine,and sophisticated procedures. ...
Cached Biology Technology:FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 2FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 3FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 4BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 2BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 3BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 4Mentice, Inc. and the Milwaukee Area Technical College (MATC) Announce Their Partnership in the Area of Procedural Medical Simulation 2
(Date:9/17/2014)... Calif. (Sept. 17, 2014) A rare genetic disorder known ... to a recent joint investigation by researchers at San ... Diego. In addition to suggesting better treatment options for ... clues into the genetic underpinnings of autism., Jacobsen syndrome ... National Institutes of Health. It occurs in a person ...
(Date:9/17/2014)... and their environmental impact recently scored a major win. ... on the bags, and Governor Jerry Brown is expected ... not yielding without a fight, according to an article ... newsmagazine of the American Chemical Society. , Alexander Tullo, ... campaign logged its first small victory in 1990 when ...
(Date:9/17/2014)... in Biomedical Informatics at IMIM (Hospital del Mar Medical ... (UPC) have recently published a study in eLife ... important role in the evolution of new proteins, some ... be discovered., Ribosomes produce proteins from the instructions found ... human genome is RNA containing information for the synthesis ...
Breaking Biology News(10 mins):A link between Jacobsen syndrome and autism 2Parts of genome without a known function may play a key role in the birth of new proteins 2
... African sanctuaries carry drug-resistant, human-associated strains of the bacteria ... chimpanzees could spread to endangered wild ape populations if ... study shows. The study by veterinarians, microbiologists and ... sequencing technology of bacterial genomes used in hospitals to ...
... forget-me-nots have been added to Flora of New Zealand . ... Island during an expedition led by Dr. Carlos A. Lehnebach. These ... the open access journal PhytoKeys . The expedition ... at the Museum of New Zealand Te Papa Tongarew a ...
... faces far greater change and risk of large-scale extinctions than ... the world,s leading marine scientists has warned. The researchers ... UK have compared events which drove massive extinctions of sea ... taking place in the seas and oceans globally today. ...
Cached Biology News:Sanctuary chimps show high rates of drug-resistant staph 2No ordinary forget-me-nots 2Sea life 'facing major shock' 2Sea life 'facing major shock' 3
... an inhibitor of caspase-3/7 ... of inhibitor required to ... be determined empirically for ... inhibitor is sufficient to ...
...
SNARE associated protein snapin, clone MGC:2717...
Human OSCAR MAb (Clone 259501)...
Biology Products: